Phenotypic screens look for specific cellular readouts, such as apoptosis. This approach does not require a prior understanding of mechanism; there is a direct link to a disease-relevant response, and the response occurs in the appropriate cellular context. However, subsequent identification of the molecular target after screening with small molecule libraries has proven challenging. Alternative approaches such as shRNA, which provides both specific target knock-down and molecular identification, do not distinguish between scaffolding and enzymatic functions and therefore have not always given the same result as target inhibition. Kinases as drug targets remain underexplored: published and clinically developed inhibitors still cover less than 10% of the kinome. Array has over a decade of experience and success in the discovery of small molecule kinase inhibitors, and has characterized a substantial collection of kinase inhibitors that can be used for phenotypic screening (Figure 1 ). These inhibitors have attractive properties: they are cell permeable with an IC50 < 1uM in at least one cell-based assay, are not cytotoxic, and collectively cover > 90% of the upstate kinase screening set. In addition, because of the chemical diversity and target coverage, kinases of potential interest can quickly be identified by de-convolution of screening data. Array has used this approach to focus on novel kinase targets and is looking for partners with phenotypic screens interested in identifying new cancer targets and discovery of new therapeutics.
